Replies to post #166800 on Biotech Values

[mcbio]

My point is ABBV will be in a strong position to dictate their share of the oral HCV market by strategically undercutting GILD on price. The Department of Veterans Affairs or correctional agencies won't care about pill count.


When the final GT1 data reads out it's important that GILD's combo meets or exceeds the the ABBV combo in all metrics. Insurance companies could potentially make a case for using the lower cost ABBV option on data weakness. Overall I think 38% is a pretty good guess by Dew.

To be clear, I'm thinking about longer-term market shares, and not just the short-term market shares when we have solely the ABBV and GILD combos on the market. Sure, ABBV may well make in-roads initially to some degree by undercutting GILD's pricing (still not sure of that 38% figure), but how effectively will ABBV be able to compete when other combos come to market that are more convenient/patient friendly which also undercut GILD's pricing?